The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation

References

• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and High-Dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Abboud R, Keller J, Slade M, et al. Severe Cytokine-Release syndrome after T cell–replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti–IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22(10):1851–1860.
   PubMed Web of Science ®Google Scholar
• Mariotti J, Taurino D, Bramanti S, et al. Severe cytokine release syndrome is a fatal complication after PBSC, but not after BM haploidentical transplantation with Post-Transplant cyclophosphamide. Blood. 2017;130(Suppl_1):665–LP - 665.
   Google Scholar
• Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(12):2431–2437.
   PubMed Web of Science ®Google Scholar
• Raj RV, Hamadani M, Szabo A, et al. Biology of blood and marrow transplantation peripheral blood grafts for T cell – replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant. 2018;24(8):1664–1670.
   PubMed Web of Science ®Google Scholar
• Abboud R, Wan F, Mariotti J, et al. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international Multi-Center collaboration. Biol Blood Marrow Transplant. 2020;26(3):S55–S56.
   Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–748.
   PubMed Web of Science ®Google Scholar
• Ureshino H, Ando T, Kizuka H, et al. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2017;36(1):324–327.
   PubMed Web of Science ®Google Scholar
• Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456–464.
   PubMed Web of Science ®Google Scholar
• Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and Meta-analysis of randomized controlled trials. Rheumatology. 2011;50(3):552–562.
   PubMed Web of Science ®Google Scholar
• Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE. Rheumatology. 2017;56(10):1746–1754.
   PubMed Web of Science ®Google Scholar
• Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology. 2012;51(5):852–857.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41(1):15–23.
   PubMed Web of Science ®Google Scholar
• Abid MB, Hamadani M, Szabo A, et al. Severity of cytokine release syndrome and its association with infections after T Cell-Replete haploidentical related donor transplantation. Biol Blood Marrow Transplant. 2020;26(9):1670–1678.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Holland T, Raad I, Boucher H, Staphylococcal Bacteremia Investigators, et al. Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia; a randomized clinical trial. JAMA. 2018;320(12):1249–1258.
   PubMed Web of Science ®Google Scholar
• Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1995;82(3):667.
   Web of Science ®Google Scholar
• Slade M, Goldsmith S, Romee R, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19(1):e12629–10.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Slade M, Dipersio JF, et al. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016;101(11):e465–e468.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Castagna L, Furst S, et al. The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplant. 2016;51(8):1134–1136.
   PubMed Web of Science ®Google Scholar
• Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121–130.
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Tey SK, Buizen L, et al. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood. 2021;137(14):1970–1979.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDS. Ann Rheum Dis. 2017;76(3):504–510.
   PubMed Web of Science ®Google Scholar
• Chaudhry H, Zhou J, Zhong Y, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo (Brooklyn). 2013;27(6):669–684.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–874.
   PubMed Web of Science ®Google Scholar
• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA J Am Med Assoc. 2011;306(23):2594–2605.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27(7):1230–1251.
   PubMed Web of Science ®Google Scholar
• Torgersen C, Moser P, Luckner G, et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg. 2009;108(6):1841–1847.
   PubMed Web of Science ®Google Scholar
• Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15(4):R183.
   PubMed Web of Science ®Google Scholar
• Abboud R, Wan F, Mariotti J, et al. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplant. 2021;56(11):2763–2770.
   PubMed Web of Science ®Google Scholar